The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy and in combination with abemaciclib, in endometrioid endometrial cancer (EEC): Results from the EMBER phase 1a/1b study.
 
Kan Yonemori
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo/Astra Zeneca; Eisai; Fujifilm; Lilly Japan; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Chugai Pharma; Eisai; Henlius; Novartis; OncXerna Therapeutics; Ono Pharmaceutical
Research Funding - AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Genmab (Inst); Haihe Pharmaceutical (Inst); Kyowa Hakko Kirrin (Inst); Lilly (Inst); MSD (Inst); Nihonkayaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Kalyan Banda
Honoraria - GlaxoSmithKline; Immunogen
Research Funding - Kineta (Inst); Lilly (Inst); MorphoSys (Inst); Pfizer (Inst); Regeneron (Inst)
 
Valentina Boni
Employment - Next Oncology; Quironsalud
Leadership - Next Oncology
Stock and Other Ownership Interests - 1TRIALSP
Honoraria - Amunix; EMD Serono/Merck; Guidepoint Global; IDEAYA Biosciences; Janssen Oncology; Loxo; MSD Oncology; Puma Biotechnology
Consulting or Advisory Role - EMD Serono/Merck; Guidepoint Global; Janssen Research & Development; Lilly; Nanobiotix; Novartis; OncoArt
Speakers' Bureau - Lilly; MSD; Solti; TACTICS
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Alkermes (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BioNTech (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genmab (Inst); Incyte (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Lilly (Inst); Loxo (Inst); Menarini (Inst); Merck (Inst); Merus (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Synthon (Inst); Tesaro (Inst); Zenith Epigenetics (Inst)
Travel, Accommodations, Expenses - Bayer; START
 
Joohyuk Sohn
Stock and Other Ownership Interests - Daiichi Sankyo (I)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol Myerss guibb (Inst); Celcuity (Inst); Daiichi Sankyo (Inst); Dragonfly Therapeutics (Inst); Eikon (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hanmi Pharm (Inst); HLB Life Science (Inst); ILDONG PHARMACEUTICAL (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Olema Oncology (Inst); Pfizer (Inst); Qurient (Inst); Roche (Inst); Samyang Holdings (Inst); Sanofi (Inst); Seagan (Inst); Sermonix Pharmaceuticals (Inst)
 
Tarek Meniawy
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Eisai; GlaxoSmithKline; MSD; Novartis; Regeneron; Sanofi
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai
 
Janine Margaret Lombard
Honoraria - AstraZeneca; Eisai; Gilead Sciences; GlaxoSmithKline; Novartis
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Lilly
 
Peter A. Kaufman
Stock and Other Ownership Interests - Amgen; Johnson & Johnson/Janssen
Honoraria - AstraZeneca; Eisai; Lilly
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Macrogenics; Merck; Pfizer; Polyphor; Roche/Genentech; Sanofi; Seagen; Sermonix Pharmaceuticals
Speakers' Bureau - Lilly
Research Funding - Eisai (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Sanofi (Inst); Sermonix Pharmaceuticals (Inst); Zymeworks (Inst)
Expert Testimony - Seagen
Travel, Accommodations, Expenses - Lilly; Polyphor; Seagen
 
Debra L. Richardson
Consulting or Advisory Role - AstraZeneca; Eisai; GlaxoSmithKline; Immunogen; Mersana; ProfoundBio
Research Funding - Aravive (Inst); Arch Oncology (Inst); ArQule (Inst); AstraZeneca (Inst); Celsion (Inst); Clovis Oncology (Inst); Deciphera (Inst); Five Prime Therapeutics (Inst); Fujifilm (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Harpoon therapeutics (Inst); Hookipa Biotech (Inst); Innovent Biologics (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Merck (Inst); Mersana (Inst); Plexxikon (Inst); Roche (Inst); Shattuck Labs (Inst); Syros Pharmaceuticals (Inst); Tesaro (Inst)
 
Laura Bender Somme
No Relationships to Disclose
 
Koji Matsumoto
Honoraria - Bayer Yakuhin; Chugai Pharma; Eisai; Kyowa Hakko Kirin; Lilly Japan; MSD K.K; Pfizer; Taiho Oncology; Takeda
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan; eisai (Inst); Lilly Japan; MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst)
 
Karthik Giridhar
Consulting or Advisory Role - AstraZeneca/Daiichi Sankyo (Inst); Exact Sciences (Inst); Gilead Sciences (Inst); Lilly (Inst); MJH Live Events (Inst); MJH Live Events (Inst); NeoGenomics Laboratories (Inst); Puma Biotechnology (Inst); Tersera (Inst)
Research Funding - Guardant Health (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - GRAIL; QuantumLeap Health
 
Jose Angel Garcia Saenz
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Exact Sciences; Gilead Sciences; Lilly; Novartis; Seagen
Speakers' Bureau - Lilly; Novartis
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Novartis; Roche
 
Hans Prenen
Honoraria - Amgen; AstraZeneca; Merck; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Biocartis; cureteq
 
Bernard Doger de Spéville Uribe
No Relationships to Disclose
 
Don S. Dizon
Stock and Other Ownership Interests - Doximity; Midi
Honoraria - UpToDate
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; GlaxoSmithKline; Pfizer
Research Funding - Bristol-Myers Squibb (Inst)
Other Relationship - Global Cancer Institute
 
Javier García-Corbacho
Research Funding - Alkermes (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Black Diamond Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen (Inst); Menarini (Inst); MSD (Inst); Novartis (Inst); Puma Biotechnology (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - BMS; Pfizer (Inst)
 
Yujia Li
Employment - Lilly; Memorial Sloan-Kettering Cancer Center (I)
Stock and Other Ownership Interests - Illumina (I); Lilly; Lilly (I); Pfizer (I)
Travel, Accommodations, Expenses - Lilly
 
Bastien Nguyen
Employment - Loxo/Lilly
 
Roohi Ismail-Khan
Employment - Eli Lilly/ Loxo Oncology
Stock and Other Ownership Interests - Lilly
 
Patrick Neven
Consulting or Advisory Role - Lilly (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst); Radius Health (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Lilly (Inst); Pfizer (Inst); Roche (Inst)